Sarepta Therapeutics (SRPT) Profit After Tax (2010 - 2026)

Sarepta Therapeutics' Profit After Tax history runs 17 years deep, the most recent figure standing at $331.0 million for Q1 2026.

• In Q1 2026, Profit After Tax rose 173.96% year-over-year to $331.0 million; the TTM figure through Mar 2026 stood at $65.1 million (up 126.19% YoY), while the FY2025 annual figure was -$713.4 million, down 403.27% from the prior year.
• Profit After Tax was $331.0 million for Q1 2026 at Sarepta Therapeutics, up from -$412.2 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $331.0 million in Q1 2026 to a low of -$516.8 million in Q1 2023.
• Historically, Profit After Tax has averaged -$81.6 million across 5 years, with a median of -$40.9 million in 2023.
• Biggest YoY gain for Profit After Tax was 2947.86% in 2025; the steepest drop was 1338.98% in 2025.
• A 5-year view of Profit After Tax shows it stood at -$109.2 million in 2022, then surged by 141.79% to $45.7 million in 2023, then soared by 248.37% to $159.0 million in 2024, then tumbled by 359.18% to -$412.2 million in 2025, then soared by 180.29% to $331.0 million in 2026.
• The last three Profit After Tax figures came in at $331.0 million (Q1 2026), -$412.2 million (Q4 2025), and -$50.6 million (Q3 2025), per Business Quant data.